The Mole Clinic, the UK’s leading private provider of skin cancer screening, has announced the appointment of Susan Veness as Chief Financial Officer.
Susan’s experience reflects a consistent theme: scaling complex, high-growth businesses while maintaining strong financial discipline.
In just the past 18 months, the clinic has expanded from four to 12 locations, with significant growth planned in the years ahead. From its inception, the organisation has been at the forefront of innovation in skin cancer diagnosis, combining technology with clinical expertise to improve accuracy and patient outcomes.
Susan’s role will be central to supporting that trajectory.
As the business enters its next phase of growth, financial leadership becomes critical, not just to scale operations, but to ensure long-term, sustainable access to early detection.
Susan joins at a pivotal moment, bringing extensive experience leading financial strategy across healthcare and technology-enabled organisations. Most recently, she was Chief Financial Officer at 18 Week Support, the UK based healthcare provider, where she oversaw financial strategy and managed financial operations.
Prior to this, Susan was CFO at leading telediagnostics platform 4ways for nearly five years, playing a key role during a period of significant growth and increasing demand for technology-enabled healthcare solutions.
Previously she was CFO at Phlexglobal, a technology and services partner to CRO and pharma, where she oversaw the company’s continued expansion and service offering evolution.
Her experience reflects a consistent theme: scaling complex, high-growth businesses while maintaining strong financial discipline.
Speaking of her appointment, Susan Veness said: “I’m delighted to be joining The Mole Clinic at such an exciting stage of its growth. The mission is clear and meaningful — to detect skin cancer early and make those services accessible to more people. I look forward to supporting the team as the business continues to expand.”
Annie Meharg, CEO at The Mole Clinic, added: “Susan brings deep financial expertise and a strong track record of supporting growing healthcare organisations. As we continue to scale, her leadership will be key to ensuring we do so in a way that is both ambitious and sustainable.”
The Mole Clinic’s mission is simple: reduce skin cancer mortality through early detection, and the company has developed high-quality screening services, making them widely accessible, and continuing to invest in the technology and expertise that underpin accurate diagnosis.
Today, over 35,000 patients visit its clinics each year across the UK, supported by specialist nurses, doctors, and advanced diagnostic technology.
For more information go to https://themoleclinic.co.uk/.
